enGene Therapeutics ENGN Institutional Ownership

enGene Therapeutics Inc. (NASDAQ:ENGN) has 61 institutional investors that have filed 13F reports for the period ending June 2026.

• Collectively, these holders controlled 71.7% of enGene Therapeutics's outstanding shares in June 2026, down from 83.6% in March 2026.
• They increased total shares held in enGene Therapeutics by 342.87% from last quarter, and the number of investors in ENGN increased 69.44% annually.
• Among the 61 funds, 57 bought more enGene Therapeutics shares, 0 sold down, and 4 held their ground.
• In total, institutional investors held 50.0Mn shares in enGene Therapeutics as of June 2026, up by 38.71Mn shares quarter on quarter, and up 9.96Mn shares year over year.
• As of June 30, 2026, FCPM III SERVICES B.V. held the largest stake in enGene Therapeutics with 9.63Mn shares, accounting for 13.82% of total shares outstanding.
• The largest buyers of enGene Therapeutics for the quarter ending June 2026 were BML Capital Management, LLC (6.67Mn), Siren, L.L.C. (6.26Mn), PERCEPTIVE ADVISORS LLC (4.82Mn), Ameriprise Financial Inc (2.68Mn), Nextech Invest Ltd. (2.32Mn).
• Business Quant data shows the 10 biggest positions in enGene Therapeutics as of June 2026 are held by FCPM III SERVICES B.V. (9.63Mn), BML Capital Management, LLC (6.67Mn), Siren, L.L.C. (6.26Mn), PERCEPTIVE ADVISORS LLC (4.82Mn), Ameriprise Financial Inc (2.68Mn), Nextech Invest Ltd. (2.32Mn), ADAR1 Capital Management, LLC (2.1Mn), Vestal Point Capital, LP (1.67Mn), ACORN CAPITAL ADVISORS, LLC (1.27Mn), Peapod Lane Capital LLC (1.1Mn).